CompletedPhase 2NCT02450552
Clinical Trial of Ezogabine (Retigabine) in ALS Subjects
Studying Amyotrophic lateral sclerosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Brian Wainger
- Principal Investigator
- Brian Wainger, MD, PhDMassachusetts General Hospital
- Intervention
- Ezogabine(drug)
- Enrollment
- 65 enrolled
- Eligibility
- 18-80 years · All sexes
- Timeline
- 2015 – 2018
Study locations (12)
- Barrow Neuological Institute, Phoenix, Arizona, United States
- Cedars-Sinai, Los Angeles, California, United States
- UC Irvine Medical Center, Orange, California, United States
- Mayo Clinic in Florida, Jacksonville, Florida, United States
- Augusta University (Georgia Regents Medical Center), Augusta, Georgia, United States
- Johns Hopkins Hospital, Baltimore, Maryland, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
- University of Michigan, Ann Arbor, Michigan, United States
- Hospital for Special Surgery, New York, New York, United States
- Duke University Hospital, Durham, North Carolina, United States
- Penn State College of Medicine Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States
Collaborators
ALS Association · GlaxoSmithKline · Harvard University · Massachusetts General Hospital
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02450552 on ClinicalTrials.govOther trials for Amyotrophic lateral sclerosis
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07401186Stimulation-Based Modulation of Spinal and Cortical Sensory PathwaysPeter C. Gerszten, MD
- RECRUITINGNCT07467187Invasive Home Ventilation in DenmarkRigshospitalet, Denmark
- RECRUITINGNCT07259980A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Participants With Superoxide Dismutase 1 (SOD-1) Amyotrophic Lateral Sclerosis (ALS)Biogen
- RECRUITINGNCT07502677Diagnostic Accuracy of SleepImage Technology for Detecting Respiratory Failure in Patients With Amyotrophic Lateral SclerosisRoyal Brompton & Harefield NHS Foundation Trust
- RECRUITINGNANCT07446114Functional Outcomes and Control Using Synchron BCI - CanadaSynchron, Inc.
- ENROLLING BY INVITATIONPHASE2, PHASE3NCT07410806HEALEY ALS Platform Trial - Regimen I NUZ-001Merit E. Cudkowicz, MD
- ENROLLING BY INVITATIONNANCT07298486Impact of Robotic Glove Use on Quality of Life, Grip Strength and Fine Motor Control in ALSNova Southeastern University
- ACTIVE NOT RECRUITINGPHASE1NCT07204977Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS)National Institute of Neurological Disorders and Stroke (NINDS)